Join DiaMedica Therapeutics for a virtual key opinion leader (KOL) event featuring Dr. Baha M. Sibai, Professor (McGovern Medical School at UTHealth Houston, Memorial Hermann Hospital), Professor Stephen Tong (The Mercy Hospital for Women, The University of Melbourne), and Professor Susan Walker (The Mercy Hospital for Women, The University of Melbourne), who will join company management to discuss the unmet need and current treatment landscape for preeclampsia, and provide an overview of DiaMedica’s Phase 2 preeclampsia clinical trial design and key endpoints.

Preeclampsia is a serious and life-threatening disease in pregnancy that typically emerges after 20 weeks of gestation, impacting both the mother and unborn child.  DM199 is a potentially disease-modifying therapy that enhances the production of endothelial nitric oxide, prostacyclin, and endothelium-derived hyperpolarizing factor, with the potential to lower blood pressure, improve endothelial function, and increase perfusion to maternal organs and the placenta. In addition, DM199 is not expected to cross the placental barrier, offering a potential safety advantage during pregnancy.

A live question and answer session will follow the formal presentations.